Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25922298 | 0.69 | PRPS1 (0.41) | PRPS1ARHTR1A | |
| SCHEMBL3037931 | 0.67 | PRPS1 (0.54) | PRPS1AR | |
| SCHEMBL3037828 | 0.65 | AR (0.47) | PRPS1AR | |
| SCHEMBL31698451 | 0.65 | ESR1 (0.41) | PRPS1AR | |
| SCHEMBL30317164 | 0.63 | PRPS1 (0.53) | PRPS1SLC6A4SLC6A2AR | |
| SCHEMBL3302667 | 0.61 | SLC6A3 (0.38) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4877523 | 0.60 | KMT2A (0.43) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL898138 | 0.59 | SLC6A3 (0.39) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL27625206 | 0.59 | AR (0.40) | PRPS1AR | |
| SCHEMBL5377115 | 0.58 | AGER (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | PRPS1 4815/4885SLC6A4 4195/4885SLC6A3 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.